What Is Ecnoglutide? Definition and What Research Reports

Definition

Ecnoglutide (reported in the literature under the development code XW003) is a synthetic, long-acting peptide analogue of glucagon-like peptide-1 (GLP-1) that was engineered so that activation of the GLP-1 receptor preferentially drives the cyclic AMP (cAMP) second-messenger pathway while recruiting little β-arrestin — a profile the discovery paper described as cAMP-biased signalling with reduced receptor internalisation (PMID 37364710). In practice the word is used two ways in the published record: as the name of a specific molecule, and as a worked example of the broader pharmacological idea that how a GLP-1 receptor agonist signals — not only how tightly it binds — may shape its metabolic effects. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about medical care or treatment.

What Class of Molecule It Is, and Where the Term Comes From

Ecnoglutide belongs to the incretin mimetic class: peptide agonists at the GLP-1 receptor, a G protein-coupled receptor. Its backbone derives from native human GLP-1, modified with amino-acid substitutions and a lipid (fatty-chain) side chain intended to extend circulating half-life and support once-weekly administration, and researchers reported this long-acting, cAMP-biased profile when they characterised the compound (PMID 37364710). Site-specific fatty-chain modification of GLP-1 receptor agonists as a half-life extension strategy had already been described in earlier peptide chemistry work reporting antidiabetic effects in preclinical models (PMID 30795583).

The "biased" part of the definition sits inside an older literature on GLP-1 receptor pharmacology. Comparative studies of exendin-4 and lixisenatide reported that GLP-1 receptor agonists differ in signalling, receptor trafficking and glucoregulatory behaviour rather than acting as interchangeable ligands (PMID 32436216). The same framework has been applied to the dual incretin agonist tirzepatide, which one pharmacology study characterised as an imbalanced and biased dual GIP and GLP-1 receptor agonist (PMID 32730231). Ecnoglutide is the term used when that concept is applied to a mono-agonist optimised for the cAMP arm.

Related Glossary Terms

• GLP-1 receptor agonist — a compound that activates the GLP-1 receptor.
• Biased agonism — preferential activation of one downstream pathway over another at the same receptor.
• cAMP — the G protein-coupled second messenger favoured by ecnoglutide in the discovery characterisation.
• β-arrestin — an adaptor protein linked to receptor desensitisation and internalisation.
• XW003 — the development code that appears alongside "ecnoglutide" in earlier reports.

How the Term Is Used in Peptide Research

"Ecnoglutide" appears across four fairly distinct literatures, and knowing which one a given mention belongs to usually clarifies what is being claimed:

1. Receptor pharmacology — papers testing whether biased signalling at the GLP-1 receptor changes metabolic outcomes.
2. Preclinical models — rodent studies of body weight and glucose handling.
3. Clinical trials — randomised studies in type 2 diabetes and in adults with overweight or obesity.
4. Reviews and syntheses — systematic reviews, network meta-analyses and drug-profile articles that place the molecule alongside other agents.

Where Ecnoglutide Appears in the Published Record

What the Published Literature Reports

On mechanism, the discovery paper reported that ecnoglutide combined long duration of action with cAMP-biased GLP-1 receptor activation and reduced β-arrestin engagement (PMID 37364710), and a later mouse study reported that a GLP-1 analogue optimised for cAMP-biased signalling produced improved weight loss in obese animals (PMID 40157531). Separate preclinical work reported that eliminating β-arrestin recruitment altogether was needed before the full metabolic benefit of a G protein-biased GLP-1 receptor agonist appeared (PMID 37795639).

In humans, a randomised, double-blind, placebo-controlled phase 2 trial in adults with type 2 diabetes reported efficacy on glycaemic endpoints together with safety data for once-weekly subcutaneous ecnoglutide (PMID 39333121). In adults with overweight or obesity, a multicentre, randomised, double-blind, placebo-controlled phase 3 trial reported significantly greater reductions in body weight with ecnoglutide than with placebo (PMID 40555243). The 52-week, multicentre, open-label EECOH-2 phase 3 trial compared ecnoglutide with dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy and was designed to test non-inferiority on glycaemic control (PMID 40854315). A 2026 drug-profile article in Drugs summarised ecnoglutide's first regulatory approvals and development history (PMID 42412371).

Adverse Events: What Studies Report

Across the clinical record for ecnoglutide, gastrointestinal complaints were the adverse events most consistently described, in line with the GLP-1 receptor agonist class generally. The phase 2 type 2 diabetes trial reported safety and tolerability alongside its efficacy endpoints, with gastrointestinal events among the reported findings (PMID 39333121), and the phase 3 obesity trial likewise reported safety outcomes for ecnoglutide compared with placebo (PMID 40555243). The 52-week EECOH-2 trial reported safety as well as glycaemic outcomes in its comparison with dulaglutide (PMID 40854315). Broader syntheses of obesity pharmacotherapy have discussed tolerability and discontinuation patterns across agents in this class (PMID 39952695, PMID 42419792). Readers wanting event-by-event rates should consult the primary reports, since this glossary entry does not reproduce trial safety tables.

Limitations of the Current Record

• Most human data come from trials sponsored during development, and the comparative literature is still thinner than for earlier-approved GLP-1 receptor agonists (PMID 42419792).
• The mechanistic case for cAMP bias rests substantially on cell-based and rodent work, which does not automatically translate to clinical outcomes (PMID 37795639, PMID 40157531).
• One phase 3 comparison was open-label rather than blinded, a design feature stated in the trial's own title (PMID 40854315).
• Peptide material supplied to laboratories is typically labelled research use only and is not a medicine; regulatory status differs from approved pharmaceutical products, and the first-approvals record is summarised elsewhere (PMID 42412371).

References

• Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog (Molecular Metabolism, 2023)
• A GLP-1 analogue optimized for cAMP-biased signaling improves weight loss in obese mice (Molecular Metabolism, 2025)
• Abolishing β-arrestin recruitment is necessary for the full metabolic benefits of G protein-biased glucagon-like peptide-1 receptor agonists (Diabetes, Obesity & Metabolism, 2024)
• Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial (Nature Communications, 2024)
• Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (The Lancet Diabetes & Endocrinology, 2025)
• Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2) (The Lancet Diabetes & Endocrinology, 2025)
• Ecnoglutide: First Approvals (Drugs, 2026)
• Emerging pharmacotherapies for obesity: A systematic review (Pharmacological Reviews, 2025)
• Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis (BMJ, 2026)
• Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (JCI Insight, 2020)
• Signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide (British Journal of Pharmacology, 2020)
• Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects (Molecules, 2019)